miR-486-5p expression pattern in esophageal squamous cell carcinoma, gastric cancer and its prognostic value

// Chuanli Ren 1, 4, * , Hui Chen 2, * , Chongxu Han 1 , Deyuan Fu 3 , Lin Zhou 1 , Guangfu Jin 4 , Fuan Wang 5 , Daxin Wang 1 , Yong Chen 6 , Li Ma 7 , Xucai Zheng 8 , Dongsheng Han 1 1 Clinical Medical Testing Laboratory, Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University, Yangzhou, China 2 Geriatric Medicine, Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University, Yangzhou, China 3 Breast Oncology Surgery, Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University, Yangzhou, China 4 Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Modern Toxicology, School of Public Health, Nanjing Medical University, Nanjing, China 5 Departments of Interventional Radiography, Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University, Yangzhou, China 6 Departments of Oncology, Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University, Yangzhou, China 7 Laboratory of Hematology, Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University, Yangzhou, China 8 Department of Head and Neck Surgery, Anhui Cancer Hospital, Hefei, China * These authors contributed equally to the work Correspondence to: Chuanli Ren, e-mail: renchl@163.com Keywords: digestive system cancers, esophageal squamous cell carcinoma, gastric adenocarcinoma, micro RNA-486-5p, prognosis Received: October 19, 2015     Accepted: February 02, 2016     Published: February 16, 2016 ABSTRACT Micro RNA (miR)-486-5p is often aberrantly expressed in human cancers. The aim of this study was to identify the prognostic value of miR-486-5p expression in digestive system cancers. Tissue microarrays were constructed with 680 samples including 185 esophageal squamous cell carcinomas (ESCCs), 90 gastric adenocarcinomas (GCs), and 60 digestive system cancer tissues from 10 ESCC, 10 GC, 10 colon, 10 rectum, 10 liver, 10 pancreatic cancer, and corresponding normal tissues. Twenty normal digestive system mucosa tissues from healthy volunteers were included as normal controls. In GC, miR-486-5p expression was decreased in 62.8% of cases (59/94), increased in 33.0% (31/94), and unchanged in 4.2% (4/94); in ESCC its expression was decreased in 66.2% (129/195), increased in 32.3% (63/195), and unchanged in 1.5% (3/195). Expression of miR-486-5p was decreased in 12, and increased in 8, of 20 cases of colon or rectum cancer; decreased in 6, and increased in 4, of 10 cases of liver cancer; and decreased in 8, and increased in 2, of 10 cases of pancreatic cancer. Multivariate and univariate regression analysis demonstrated that low/unchanged miR-486-5p predicted poor prognosis in ESCC (hazard ratio [HR], 4.32; 95% confidence interval [CI], 2.62–7.14; P < 0.001; HR, 3.88; 95% CI, 2.43–6.22; P < 0.001, respectively) and GC (HR, 2.46; 95% CI, 1.35–4.50; P = 0.003; HR, 2.55; 95% CI, 1.39–4.69; P = 0.002, respectively). MiR-486-5p might therefore be an independent tumor marker for evaluating prognosis in patients with ESCC or GC.